Tyra Biosciences Inc. (TYRA) is having a rough Wednesday. The biotech's stock dropped sharply after the company shared initial results from its Phase 2 SURF302 trial, which tested an oral drug called dabogratinib in patients with a specific type of bladder cancer. The data provided clinical proof of concept, but the response rates weren't quite what investors were hoping for.

The study focused on patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. That's a mouthful, but essentially it's a form of bladder cancer that hasn't invaded the muscle yet, and it has a particular genetic marker that dabogratinib targets.

Exposure Matters: Higher Drug Levels, Better Responses

Here's the interesting part: the drug's effectiveness seemed to depend on how much of it was in the patient's system. Among 26 evaluable patients, those who achieved target exposure levels above a certain threshold had an overall response rate of 86%, compared to 58% for those below it.

This exposure-response relationship was most pronounced in patients with multiple marker lesions, which supports the company's decision to move forward with a 60 mg once-daily dose for adjuvant settings where there's minimal disease burden.

At that 60 mg dose, the complete response rate was 57%. For the pooled 50 mg and 60 mg cohort, it was 50%.

Analyst Take: Good, But Not Good Enough

William Blair analyst Sami Corwin noted that the stock's plunge makes sense: 57% is well below the 70%-80% complete response rate that would have been considered a successful outcome. The readout was more nuanced than expected, and investors will likely need to recalibrate their expectations.

That said, Corwin believes the data still supports moving into adjuvant Phase 3 development and preserves a viable path to generating clinically meaningful disease-free survival benefits. In other words, the drug might still have a future, even if this particular data point wasn't a home run.

What's Next: Bigger Doses and Regulatory Talks

Tyra isn't throwing in the towel. The company plans to finish enrolling the 60 mg group and also start a 70 mg daily cohort to evaluate tumor ablation. Management also intends to consult with health authorities about Phase 3 trial designs and dosing.

There's also some early encouraging news from another study. In the SURF303 trial for upper tract urothelial cancer, the first patient receiving 60 mg daily achieved a complete response at three months, with zero adverse events. That's a small but promising signal.

As for the stock, Tyra Biosciences shares were down 21.60% to $20.95 at the time of publication Wednesday, according to market data.

So, is this a disaster or just a bump in the road? The market seems to think it's closer to the former, at least for now. But with a clear path forward and more data on the horizon, the story isn't over yet.